AnaptysBio, Inc. (NASDAQ:ANAB) Insider Sells $347,230.40 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Eric J. Loumeau sold 8,720 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.82, for a total value of $347,230.40. Following the transaction, the insider now owns 7,020 shares in the company, valued at $279,536.40. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

AnaptysBio Stock Performance

AnaptysBio stock traded down $1.22 during midday trading on Tuesday, hitting $37.50. 340,978 shares of the company were exchanged, compared to its average volume of 329,314. The business has a fifty day simple moving average of $35.23 and a two-hundred day simple moving average of $27.63. The firm has a market capitalization of $1.02 billion, a PE ratio of -6.11 and a beta of -0.29. AnaptysBio, Inc. has a fifty-two week low of $13.36 and a fifty-two week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The firm had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. As a group, equities analysts expect that AnaptysBio, Inc. will post -6.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Truist Financial boosted their price target on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. JPMorgan Chase & Co. lifted their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of AnaptysBio in a research report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, AnaptysBio has an average rating of “Moderate Buy” and a consensus price target of $50.30.

Institutional Investors Weigh In On AnaptysBio

Several hedge funds have recently modified their holdings of ANAB. Frazier Life Sciences Management L.P. raised its holdings in AnaptysBio by 140.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after purchasing an additional 1,265,891 shares during the period. First Light Asset Management LLC increased its position in shares of AnaptysBio by 56.4% in the fourth quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock valued at $26,500,000 after buying an additional 446,372 shares in the last quarter. Great Point Partners LLC raised its stake in shares of AnaptysBio by 9.2% during the 4th quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock worth $20,927,000 after buying an additional 82,648 shares during the period. Franklin Resources Inc. lifted its position in shares of AnaptysBio by 22.7% during the 4th quarter. Franklin Resources Inc. now owns 405,115 shares of the biotechnology company’s stock valued at $8,678,000 after buying an additional 75,025 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in AnaptysBio by 38.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 306,633 shares of the biotechnology company’s stock valued at $7,684,000 after acquiring an additional 84,795 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.